Cargando…

Cyclic peptide drugs approved in the last two decades (2001–2021)

In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huiya, Chen, Shiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729179/
https://www.ncbi.nlm.nih.gov/pubmed/35128405
http://dx.doi.org/10.1039/d1cb00154j
_version_ 1784626884123820032
author Zhang, Huiya
Chen, Shiyu
author_facet Zhang, Huiya
Chen, Shiyu
author_sort Zhang, Huiya
collection PubMed
description In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective.
format Online
Article
Text
id pubmed-8729179
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-87291792022-02-04 Cyclic peptide drugs approved in the last two decades (2001–2021) Zhang, Huiya Chen, Shiyu RSC Chem Biol Chemistry In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective. RSC 2021-11-05 /pmc/articles/PMC8729179/ /pubmed/35128405 http://dx.doi.org/10.1039/d1cb00154j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Zhang, Huiya
Chen, Shiyu
Cyclic peptide drugs approved in the last two decades (2001–2021)
title Cyclic peptide drugs approved in the last two decades (2001–2021)
title_full Cyclic peptide drugs approved in the last two decades (2001–2021)
title_fullStr Cyclic peptide drugs approved in the last two decades (2001–2021)
title_full_unstemmed Cyclic peptide drugs approved in the last two decades (2001–2021)
title_short Cyclic peptide drugs approved in the last two decades (2001–2021)
title_sort cyclic peptide drugs approved in the last two decades (2001–2021)
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729179/
https://www.ncbi.nlm.nih.gov/pubmed/35128405
http://dx.doi.org/10.1039/d1cb00154j
work_keys_str_mv AT zhanghuiya cyclicpeptidedrugsapprovedinthelasttwodecades20012021
AT chenshiyu cyclicpeptidedrugsapprovedinthelasttwodecades20012021